The BRCA1 Exon 13 Duplication Screening Group * Recently, a 6-kb duplication of exon 13, which creates a frameshift in the coding sequence of the BRCA1 gene, has been described in three unrelated U.S. families of European ancestry and in one Portuguese family. Here, our goal was to estimate the frequency and geographic diversity of carriers of this duplication. To do this, a collaborative screening study was set up that involved 39 institutions from 19 countries and included 3,580 unrelated individuals with a family history of the disease and 934 early-onset breast and/or ovarian cancer cases. A total of 11 additional families carrying this mutation were identified in Australia (1), Belgium (1), Canada (1), Great Britain (6), and the United States (2). Haplotyping showed that they are likely to derive from a common ancestor, possibly of northern British origin. Our results demonstrate that it is strongly advisable, for laboratories carrying out screening either in English-speaking countries or in countries with historical links with Britain, to include within their BRCA1 screening protocols the polymerase chain reaction-based assay described in this report.
family. Haplotype data suggested a common founder for all these families.
To estimate the frequency and geographic diversity of carriers of this duplication, which will not be identified if not specifically sought, a collaborative study was set up. This involved 39 institutions in which the screening for ins6kbEx13 was done by PCR ( fig. 1 ) using specific primers and a positive control. A total of 3,580 unrelated individuals with a family history of breast and/or ovarian cancer who were from 19 different countries (Australia, Austria, Belgium, Canada, Finland, France, Germany, Great Britain, Hungary, Ireland, Israel, Italy, the Netherlands, Norway, Spain, Sweden, Switzerland, Turkey , and the United States) were screened. To be enrolled, the family histories had to fulfill at least one of the following criteria: (1) at least three cases of female breast and/or ovarian cancer; (2) at least one case of female breast cancer and one case of male breast cancer; (3) one case of female breast cancer diagnosed at age !50 years and one case of ovarian or female breast cancer; (4) one case of female breast cancer and one case of ovarian cancer in first-degree relatives; (5) one case of female breast cancer and one case of female bilateral breast cancer; or (6) two cases of ovarian cancer. This heterogeneous sample is representative of the diversity of patients who attend clinics for individuals at high risk for cancer. At the time of the analysis, the whole coding sequence and the splice sites of the BRCA1 and BRCA2 genes had been screened for the presence of mutations
Figure 1
Schematic representation of BRCA1 exon 13 duplication. The location and orientation of the dup13F (GAT TAT TTC CCC CCA GGC TA) and dup13R (AGA TCA TTA GCA AGG ACC TGT G) primers are represented, along with the position of the 6-kb duplicated region and of the 1.1-kb PCR fragment generated with dup13F/R. Blackened boxes denote exons; dotted lines denote intron 12; and broken lines denote intron 13. in 61% and 37%, respectively, of the families; the screening had not been completed in 31% (BRCA1) and 43% of them (BRCA2); it had not been attempted in 8% (BRCA1) and 20% (BRCA2). From this series of families, 1,831 were recruited and screened in English-speaking countries, and 10 apparently independent families were found to carry the duplication in Australia (1), Canada (1), Great Britain (6), and the United States (2) (table 1). No duplications were found in the 1,749 families who were recruited and screened in non-English-speaking countries (table 2) . Ten of the institutions involved in this project also sought the presence of the duplication in 934 additional samples, mainly breast cancer cases selected for an early age at onset (table 3) . One non-English-speaking duplication carrier was found in this second series: a Belgian woman with breast cancer diagnosed at age 34 years whose mother also developed breast cancer. If we also include the 4 families previously identified (Puget et al. 1999a ), a total of 15 apparently unrelated families have been found to carry ins6kbEx13 (table 4). As seen with the other recurrent mutations (Tonin et al. 1996) , these 15 families display a spectrum of different breast and ovarian cancer phenotypes.
Haplotype analysis was conducted with seven polymorphic short-tandem-repeat markers within or flank- ing the BRCA1 locus and spanning ∼1.9 Mb (from centromere to telomere, these markers are D17S1185, D17S1321, D17S1323, D17S1322, D17S855, D17S1326, and D17S1325; data not shown). In 8 of the 15 families, a single sample was available; thus, it was not possible to determine phase. Nevertheless, all exon 13-duplication carriers had genotypes compatible with their sharing the same haplotype. Because the particular alleles shared by duplication carriers at D17S1185 and D17S855 have population frequencies !15%, we can conclude that this duplication has most likely spread from a common ancestor. Unfortunately, because of an insufficient number of families in which haplotypes could be determined, it was not possible to accurately date this mutation. We then tried to determine where the duplication originated. The origins of three of the families positive for the duplication could not be traced (table 4) . However, the remaining ones are, in all but one case, compatible with the assumption that the ancestor for this mutation was British, because they are either of British descent or from countries-Ireland, Portugal, and Belgium-that have trading or other historical links with Britain. Five of the British families are from northern England, mainly Yorkshire, suggesting a northern British origin for the ancestor of this mutation. The exception is a U.S. family Puget et al. (1999a) .
of Norwegian and Swedish ancestries. Another possibility is that the duplication could be of Viking origin, since all the countries mentioned above also had contact with Vikings. However, against this possibility, no duplication carrier has been identified in Sweden or in Norway; but the number of families screened was low in both countries (29 and 19, respectively; . Haworth, personal communication) . In conclusion, the BRCA1 exon 13 duplication is most likely a founder mutation distributed mainly in English-speaking countries or in countries with historical links with Britain. It would be strongly advisable, for laboratories carrying out screening for BRCA1 mutations in these countries, to include within their protocols the PCRbased assay described here. This study emphasizes once more the necessity of screening not only for mutations in the coding sequence and splice sites but also for gene rearrangements, when one is analyzing for the presence of disease-causing mutations in the BRCA1 gene.
